Please assess the completion status of the following clinical trial:

Trial Title: Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18-55 years~* Symptomatic uterine fibroids~* Being prescribed UPA as a treatment for symptomatic uterine fibroids according to regular practice.~Exclusion Criteria:~* Pregnancy~* Breastfeeding~* Previous or active hepatic disease~* Transaminase (AST,ALT) blood levels higher than 3 times the upper normal limit.~* Bilirubin blood levels higher than 3 times the upper normal limit.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- UPA Treatment (Type: None): Women who had completed a full 12-week treatment course of Ulipristal Acetate for symptomatic uterine fibroids since September 2018

Based on this trial design, predict the completion outcome and termination type (if applicable).